Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Etavopivat
Catalog No.: PC-72959Not For Human Use, Lab Use Only.
Etavopivat (FT-4202) is a novel oral activator of PKR that decreases 2,3-DPG levels and hence would increase the HbS O2 affinity to reduce sickling.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Etavopivat (FT-4202) is a novel oral activator of PKR that decreases 2,3-DPG levels and hence would increase the HbS O2 affinity to reduce sickling.
FT-4202 increases the hemoglobin S O2 affinity to reduce sickling and improve RBC membrane deformability.
Etavopivat (FT-4202) increased Hb-oxygen affinity and reduced sickling under deoxygenation in ex vivo RBCs from donors with sickle cell disease (SCD).
Oral administration of FT-4202 increases Hb and improves RBC parameters in BERK mice.
Etavopivat is currently being evaluated in clinical trials for the treatment sickle cell disease (SCD).
| M.Wt | 457.501 | |
| Formula | C22H23N3O6S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Shrestha A, et al. Blood Adv. 2021 May 11;5(9):2385-2390.
2. Forsyth S, et al. Clin Pharmacol Drug Dev. 2022 Jan 12.
3. Schroeder P, et al. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
